Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13919712 | 0.89 | TPSAB1 (0.47) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL13521689 | 0.87 | TPSAB1 (0.47) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL14703486 | 0.83 | HDAC3 (0.51) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL13521694 | 0.83 | HDAC3 (0.50) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL13875714 | 0.82 | HDAC3 (0.51) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL14703494 | 0.81 | HDAC3 (0.54) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL13908255 | 0.80 | TPSAB1 (0.42) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL13933216 | 0.80 | TPSAB1 (0.42) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL14703491 | 0.80 | HDAC3 (0.48) | TPSAB1HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL13521690 | 0.79 | HDAC3 (0.46) | TPSAB1HDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | ALLACCEM, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100004218-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY | ALLACCEM, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105262-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | PAICS, KRTCAP2, OSTC | TPSAB1 3198/4885HDAC1 758/4885HDAC6 932/4885 |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | TPSAB1 1043/4885HDAC1 857/4885HDAC6 1072/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | TPSAB1 2337/4885HDAC1 480/4885HDAC6 944/4885 |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | PCSK9, HMGCR, CETP | TPSAB1 4382/4885HDAC1 715/4885HDAC6 2183/4885 |
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | TPSAB1 2266/4885HDAC1 448/4885HDAC6 624/4885 |
| US-20100004218-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY | PKD1, PKD2, PAICS | TPSAB1 3682/4885HDAC1 2165/4885HDAC6 2676/4885 |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | BMP2, BMP1, BMP6 | TPSAB1 1170/4885HDAC1 639/4885HDAC6 2060/4885 |
| US-20080275141-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | TPSAB1 2266/4885HDAC1 448/4885HDAC6 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.